Carter Caldwell

As the Penn Medicine Co-Investment Program’s inaugural Director, Carter drives Penn Medicine's investments in the cell therapy, gene therapy, mRNA, lipid nanoparticle, and connected health spinouts. Utilizing multiple decades of experience as both an entrepreneur and an investor, he sources investment opportunities, helps spinouts raise capital, manages relationships with co-investors, completes due diligence, and supports the governance of the funded companies. Carter has spent much of his career in venture capital and focused on new investments in the Healthcare IT, SaaS and Enterprise Software, AI, and Fintech industries, among others. He was previously a Managing Director with Cross Atlantic Capital Partners, a venture capital firm with 4 funds and over $500 million under management. He has a strong technology background, having founded and managed two software companies. Carter founded and served as COO of Quazant Technology, the developer of the Transaction Accelerator®, a high-speed transaction-processing database used in the Financial Services, Telecommunications and Enterprise Resource Planning industries. Prior to Quazant, Carter served as Director of Corporate Development and Product Manager at Acorn Systems, an activity-based cost analysis software and services company which was acquired by Ignite Technologies in July 2014. Carter holds an MBA from Columbia University and a BA in Philosophy, Politics and Economics from the University of Pennsylvania.